tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lim SW et al. Ginseng extract reduces tacrolimus-induced oxidative stress by modulating autophagy in pancreatic beta cells. 2017 Lab. Invest. pmid:28759009
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
Willerth SM Localized Tacrolimus Delivery Repairs the Damaged Central Nervous System. 2017 EBioMedicine pmid:29195745
Ma X et al. Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury. 2017 Biomed. Pharmacother. pmid:28633129
Gu K et al. Atypical pneumonia due to human bocavirus in an immunocompromised patient. 2017 CMAJ pmid:28507089
Kim YJ et al. Two cases of hydroa vacciniforme-like lymphoproliferative disease controlled by anti-inflammatory agents. 2017 Photodermatol Photoimmunol Photomed pmid:28543883
Zong YP et al. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. 2017 World J Pediatr pmid:28540692
Seo SR et al. Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis. 2017 Acta Derm. Venereol. pmid:28512670
Undre N and Dickinson J Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. 2017 BMJ Open pmid:28377389
Ericzon BG et al. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. 2017 Clin Transplant pmid:28295581
Lawrance IC et al. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. 2017 Clin. Gastroenterol. Hepatol. pmid:28286194
Smolders EJ et al. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? 2017 Int. J. Antimicrob. Agents pmid:28185946
Nishiya Y et al. A new efficient method of generating photoaffinity beads for drug target identification. 2017 Bioorg. Med. Chem. Lett. pmid:28108248
Wungwattana M and Savic M Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. 2017 Transpl Infect Dis pmid:28067989
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Nakamura K et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. 2017 Eur. J. Pharmacol. pmid:27993641
Gelens MACJ et al. No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure. 2017 J. Diabetes Complicat. pmid:28720321
Soiffer RJ et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 2017 J. Clin. Oncol. pmid:29040031
Chen P et al. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. 2017 J Clin Pharm Ther pmid:27885697
Grinyó JM et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27889299